Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662960 | 0.89 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL29507776 | 0.89 | NR1H2 (0.54) | P2RX7SMN1; SMN2 | |
| SCHEMBL22650493 | 0.89 | NR1H2 (0.54) | P2RX7SMN1; SMN2 | |
| SCHEMBL5913752 | 0.88 | P2RX7 (0.48) | P2RX7MKNK1 | |
| SCHEMBL1584703 | 0.87 | CPS1 (0.46) | P2RX7 | |
| SCHEMBL28692485 | 0.86 | ALDH1A1 (0.54) | P2RX7 | |
| SCHEMBL1583488 | 0.85 | MEN1 (0.51) | P2RX7SMN1; SMN2 | |
| SCHEMBL30734152 | 0.85 | MEN1 (0.51) | P2RX7SMN1; SMN2 | |
| SCHEMBL1583532 | 0.83 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL22532774 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661435-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2661435-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2661435-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012062759-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062759-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | P2RX7 132/4885SMN1; SMN2 1355/4885MKNK1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.